Objective: Postherpetic neuralgia (PHN) is a neuropathic sequelae in 8% to 27% of individuals with prior varicella zoster virus infection and herpes zoster resulting in retrograde demyelination, neurotoxic reactive oxygen species levels, and proinflammatory cytokine activation of microglia. Pain management strategies are well documented, but not always effective. Laser therapy has shown utility in nerve injury-related pain disorders and was considered a potentially efficacious intervention.
Results:
The author reports a case of PHN of 15-year duration resistant to prior interventions. Weekly laser therapy treatment over 8 weeks resulted in reduced 0 to 10 Numeric Pain Scale score from 8 to 0, Neuropathy Pain Scale Questionnaire total score from 39 to 4, and allodynia over a 60 cm 2 surface area of the upper trunk and posterior arm totally resolved, with resolution continued at 14-month follow-up.
Discussion: Theoretically, laser therapy induced tissue changes in this case occurring at and below the skin surface altering inflammatory and excitatory peripheral mechanisms noted to take place in the PHN patient. Peripheral nociceptor firing must be brought back to normal thresholds to resolve such chronic neuropathic pain and inhibit the possible central sensitization component. Anti-inflammatory cytokines, growth factors, nitric oxide, adenosine triphosphate (ATP), and other mechanisms stimulated by laser therapy as noted in medical literature may be central to the favorable response seen in this patient. Controlled clinical trials of class 4 laser therapy in the PHN patient population with similar doses would be beneficial to determine if this is an effective treatment option in PHN.
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OBJECTIVE
Postherpetic neuralgia (PHN) is diagnosed when herpes zoster (HZ) pain persists >3 months after the lesions have healed. It is estimated that one of 3 individuals will develop HZ in their lifetime. The neuropathic pain of PHN is often intermittent and not necessarily correlated with external stimuli. The risk of developing PHN increases with age with <5% of cases under 60 years old, 10% in greater than 60, and 20% in those greater than 80. 1 Harpaz et al 2 also noted a similar age-related trend. The incidence of PHN is estimated at 9% to 19% of all HZ cases. 3 Qualityof-life complications can be disabling with the most common being anxiety and depression, enjoyment of life, mood, and sleep. 4 HZ frontline treatments include antivirals and analgesics. These can help reduce the rash and pain levels, but cannot eliminate the chance of developing PHN. As antivirals reduce replication, prompt use is thought to lessen the chance of development and the combined use of gabapentin and acyclovir in HZ have shown a decreased incidence of PHN at 3-and 6-month follow-up. 5, 6 Studies have shown laser therapy may be of benefit in pain disorders, but no studies treating PHN with laser therapy were found using Pubmed, BioMed Central, Trip Database, Clinical Trials.gov, and the National Guideline Clearinghouse. A systematic review of the inhibitory effects of low level laser therapy on peripheral nerves suggested a mechanism of reducing acute pain by direct inhibition of peripheral nociceptors. Long-term reduction in chronic pain through spinal cord slowing of conduction velocity and reduced compound action potentials is suggested. 7 Rochind et al 8 reported beneficial effects of laser therapy on activation of nerve cells, their growth, and axonal sprouting, and therefore may be considered a potential treatment for nerve injury.
METHODS
A 73-year-old woman presented with the report of right upper back and shoulder blade pain into the back of the right arm that was burning, constant, aggravated by touch, and improved by loose clothing. The 3-day average numeric pain score and a Neuropathy Pain Scale Questionnaire total intensity score was calculated as a sum of the 10 individual descriptor categories, each of which has a 0 to 10 possible score. She reported having a shingles outbreak 15 years prior and was placed on antiviral medication within 48 hours of onset with no pain improvement 1 week later. Chiropractic manipulation and acupuncture therapies were added in the following weeks and months. Pain clinic referral was made 23 months post diagnosis for epidural steroid injections, which were ineffective. She entered a 1-year capsaicin patch clinical trial 7 years post onset which partially reduced the total area of pain. One year later, an oral medication (unknown) clinical trial was entered, but discontinued due to adverse side effects. She was not taking pain medication at intake or throughout her course of care because the side effects impaired daily function. Dietary supplements were: flax seed, oral vitamins B 12 , C, E, D3, and multivitamin with iron. Review of systems was unremarkable and family history was negative for similar symptom, and for neurological or connective tissue disorders.
Examination revealed shingles scarring and hyperpigmentation over the right upper thoracic, posterior arm region with no extremity trophic changes or lymphadenopathy. Extreme sensitivity to light and sharp touch brushing the skin using a closed and open paper clip was reported over a 5 cm wide by 12-cm area (60 cm 2 ), which began 3 cm lateral to T1-T3 spinous processes and continued down the posterior arm to the medial right elbow and superior axilla in the C8-posterior T1 dermatome distribution ( Fig. 1 ). This correlates with the International Association for the Study of Pain definition of allodynia. Upper and lower extremity muscle stretch reflexes were + 2/4, Babinski down-going, with no focal motor deficit, negative cervical compression, and nerve tension signs. Cervical and thoracic range of motion was full, without pain or referral. Spinal imaging was declined and no prior studies were available. Blood work revealed normal range glucose and thyroid function, B 12 was high and folic acid was within normal range.
The patient was diagnosed with PHN. A class IV laser therapy trial was initiated utilizing a progressive dose increase to limit potential post laser ache sometimes seen in treating neuropathies. The treatment plan included laser therapy once per week for 8 weeks utilizing the LCT-1000 dual diode, simultaneous 810 and 980 nm therapeutic laser (LiteCure, LLC 250 Corporate Blvd. Suite B, Newark, DE 19702 http://litecure.com/medical/our-products/lasers/lct-1000/). Power ranged from 2 to 4 W from first to last treatments. All were delivered with 50% duty cycle pulsing at 10 Hz during active phase, 2.5 cm diameter aperture, scanning 2.5 to 5 cm per second in a grid pattern beginning over the suspect spinal dorsal root ganglia, mapped area of tissue sensitization, as well as area perimeter of 2.5 cm (170 cm 2 total), followed by holding up to 5 seconds per irradiated spot moving in the same grid pattern, with a treatment time 10 minutes. The energy density delivered ranged from 3.5 to 7.1 J/cm 2 and the power density ranged from 0.42 to 0.82 W/cm 2 ( Fig. 1 
RESULTS
The numeric pain score, Neuropathy Pain Scale, and total allodynia surface area all showed decreases over the 8-week treatment course. A final evaluation was performed at week 9 with pain scores of 0 and comparable skin sensitivity to light touch as the noninvolved contralateral limb. The 0 to 10 Numeric Pain Scale score improved from 8 to 0, Neuropathy Pain Scale total score from 39 to 4, and allodynia over a 60 cm 2 surface area of the upper trunk and posterior arm totally resolved, with resolution continued at 15-month follow-up (Fig. 2) . Mild tingling was reported during irradiation. No serious adverse side effects were reported, although the patient reported a tolerable aching sensation in the irradiated area for several days following the initial treatment.
Seven weeks posttreatment, the patient returned reporting a burning pain of 4/10 in the right upper back. Laser therapy was applied at the prior 4 W, 1200 J protocol with the report of mild tingling over the area of irradiation. Thirteen month follow-up revealed no PHN symptoms and no sensitization to light touch.
DISCUSSION
HZ is thought to develop by retrograde migration of varicella zoster virus from ganglion to skin. Demyelination can be seen in areas of mononuclear cell infiltration and microglial proliferation. The exact mechanism of progression from HZ is not known, but an inflammatory component has been shown to exist by activation of microglia. A respiratory burst occurs to generate a large population of reactive oxygen species to harm the pathogen, but a neurotoxic effect can cause secondary nerve cell damage. 9 T helper-1(Th1) cells predominate and result in proinflammatory cytokine production. It has been demonstrated that both HZ and PHN patients exhibit significantly elevated levels of interleukin (IL)-1B, IL-6, tumor necrosis factor (TNF)-a, IL-8, and IL-10 over noninfected controls. HZ patients with higher pain levels had higher IL-6 levels during the acute phase and had a greater tendency to develop PHN. 10 The European Federation of Neurological Societies Guidelines on the Pharmacologic Treatment of Neuropathic Pain including PHN recommended treatments including; tricyclic antidepressants, gabapentin, pregabalin, tramadol and opioids, topical lidocaine, and capsaicin patch. 11 In addition, Argoff reports good efficacy with extended release morphine and oxycodone and no impact with oral corticosteroids. Invasive procedures such as botulinum toxin, sympathetic block, intrathecal methylprednisolone, spinal cord stimulation were viewed impractical because of short-term relief or expense. Skin resection was proven ineffective. 12 A live attenuated varicella zoster booster vaccine, Zostavax has been shown to decrease incidence of HZ by 51%, PHN by 67%, and 73% in severe long-lasting pain was observed in the Shingles Prevention Study. 13, 14 Additional potential treatments for PHN from conventional and complementary/alternative medicine approaches including: paravertebral anesthetic block, percutaneous nerve stimulation, acupuncture, acupuncture/ acupressure combination, liquid nitrogen spray cyrotherapy, and intravenous vitamin C. [15] [16] [17] [18] [19] [20] [21] [22] [23] Chronic pain is the leading cause of disability in the world. The majority of new approaches to treat neuropathic pain have been "off-label" existing drugs showing a need for new innovative procedures. 24 Laser therapy is gaining more presence in the rehabilitation community, including chronic pain management. 25 It is not a commonly used modality in PHN. The origin of laser therapy is European, beginning with tissue healing experiments by Andre Mester, MD at Semmelweis University in Turkey in 1967. Low-level laser therapy devices are cleared by the US Food and Drug Administration under the American National Standards Institute (ANSI) Z136.1 Federal Laser Performance Standard based on the potential to harm eye and skin tissue. Both class 3b lasers (5 to 500 mW) and class 4 lasers (over 500 mW) require an ANSI-approved a laser warning sign that must be placed on the treatment room door. Individuals present must wear ANSI-approved goggles for the wavelengths of the laser in use provided by the manufacturer. The clearances are also based on FDA Premarket Notification/510(k) process as adjunctive devices for the safe temporary relief of pain based on clinical data to support the claim (http://www.fda.gov. search: Litecure, LLC 510(k)). Class 3b and class 4 therapeutic lasers can cause thermal injury if not utilized as recommended by the manufacturer and should be performed only after completing a proper training program and with patient comfort. Overstimulation can occur possibly causing inhibition of cellular activity or possible discomfort lasting hours to days. Laser therapy has been shown to be safe with minimal side effects when energy density is delivered within the range of prior published parameters. 26 Caution should be exercised when quoting total and average dose recommendations per area as absolute, as this is an ever evolving process based on in vitro and in vivo studies.
Understanding the physiological response of laser/tissue interaction in photobiomodulation is imperative before treating patients. Laser therapy uses coherent, nonablative laser energy for biostimulation with wavelengths commonly in the 500 to 1000 nm range. Gryko and Zajac report an optical window for laser therapy as 550 to 1064 mm, and suggest tissue penetration of 50 to 80 mm. The infrared 800 to 1000 nm range as having the lowest absorption of both melanin and water and therefore increasing photon delivery to deeper structures. They suggested that an idea dose range for biostimulation is between 2 and 12 J/cm 2 although much higher energy densities have also been reported. Photon absorption and energy transfer within the cell increases its total energy and presumably increasing metabolism, electrolyte exchange, circulation of blood and lymph, and nerve excitability. 27 This activates photoreceptors, which are chromophores including, but not limited to hemoglobin, cytochrome c oxidase, myoglobin, flavins, flavoprotiens, and porphyrins. Mitochondria are primary receptors due to the presence of mixed valence copper-containing cytochrome c oxidase causing respiratory chain increases of ATP production. ATP can significantly alter cell metabolism in suppressed or damaged cells. 28 Nitric oxide (NO) within the mitochondrial membrane can bind oxygen and inhibit cytochrome c oxidase. 29 Proper laser dosing has been shown to cleave NO from the copper bonding sights on cyclooxygenase and increase cellular respiration. 30 Laser therapy studies have shown reductions some of the proinflammatory metabolites as seen in PHN including; TNF-a, IL-1b, IL-6, and cyclooxygenase-2 31-33 TNF-a has been shown to be involved in peripheral neuropathic pain and upregulation at the spinal cord dorsal root ganglion to influence nociceptive signaling. 34 Experimental studies have shown positive effects of laser therapy on injured peripheral nerve regeneration. 35 Although no studies have been published in the last decade using this modality for PHN these are possible mechanisms contributing to the long-term pain reduction seen in this single case based on the cited studies and the inflammatory and cytotoxic damage parallels seen in PHN.
Theoretically, laser therapy-induced tissue changes in this case occurring at and below the skin surface altering inflammatory and excitatory peripheral mechanisms noted to take place in the PHN patient. Peripheral nociceptor firing must be brought back to normal thresholds to resolve such chronic neuropathic pain and inhibit the possible central sensitization component. Anti-inflammatory cytokines, growth factors, NO, ATP, and other mechanisms stimulated by laser therapy as noted in medical literature may be central to the favorable response seen in this patient. Controlled clinical trials of class 4 laser therapy in the PHN patient population with similar doses would be beneficial to determine if this is a safe and effective treatment option in PHN.
